The two BPC-157 forms covered by the recommendation The committee question covered two related bulk drug substances: BPC-157 free base and BPC-157 acetate
No evidence package for common commercial routes FDAs briefing found no adequate human studies for the commonly proposed oral, subcutaneous, nasal, or transdermal routes
The cagrilintide dosage with tirzepatide guide explores this concept in detail
Greibe E, Kornerup LS, Juul CB, et al
The same group subsequently reported that BPC-157 modulates vasomotor tone by enhancing phosphorylation of Src, caveolin-1, and eNOS, and that the peptide reduces caveolin-1/eNOS binding a step that releases eNOS from caveolar inhibition and permits nitric oxide generation (Hsieh et al., 2020)